Premium
Malignant uterine smooth muscle tumors: Role of etoposide, cisplatin, and doxorubicin (EPA) chemotherapy
Author(s) -
Resnik E.,
Chambers S. K.,
Carcangiu M. L.,
Kohorn E. I.,
Schwartz P. E.,
Chambers J. T.
Publication year - 1996
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199611)63:3<145::aid-jso3>3.0.co;2-d
Subject(s) - medicine , etoposide , chemotherapy , cisplatin , surgery , doxorubicin , stage (stratigraphy) , progressive disease , urology , paleontology , biology
Background Nearly 80% of patients with malignant uterine smooth muscle tumor will suffer local relapse and/or distant metastases after initial surgical resection. There is no convincing evidence that the addition of pelvic radiation improves the outcome. However, adjuvant chemotherapy might be an appropriate therapeutic modality. Methods Between 1986 and 1991, 13 consecutive patients with malignant uterine smooth muscle tumors were treated at Yale‐New Haven Hospital with a combination chemotherapy containing etoposide 100 mg/M 2 on days 1 and 2, cisplatin 50 mg/M 2 on day 1, and doxorubicin 50 mg/M 2 on day 1, repeated every 28 days. Six patients had Stage I disease, one patient had Stage III disease, and six patients had Stage IV disease. The number of cycles ranged from 2 to 9. Results The median follow‐up was 30 months (range 4–81). The mean overall survival for the group was 43.1 ± 6.7 months, with the progression‐free interval of 25.5 ± 8.0 months. Of the seven patients with evaluable disease, one patient had complete response and one had partial response (total response rate of 28.6%). Of the six patients treated adjuvantly, three recurred at 9, 33, and 59 months (recurrence rate of 50%). Conclusions We conclude that this combination has only modest activity against malignant uterine smooth muscle tumors at the schedule and doses tested. © 1996 Wiley‐Liss, Inc.